XML 23 R14.htm IDEA: XBRL DOCUMENT

Other Receivables, net	6 Months Ended
Jun. 30, 2026
Other Receivables, Net, Current [Abstract]
Other Receivables, net	6. Other Receivables, net In April 2024, entinostat received marketing approval in China, and as a result, the Company recorded $3.5 million of milestone revenue in 2024. The Company had recorded a $3.7 million receivable related to milestones (plus accrued interest) under the license agreement with Eddingpharm in 2025, which remains outstanding as of June 30, 2026. As the receivable remains outstanding, and the Company has assessed the amount as non-recoverable, the Company recorded a full reserve against the asset as a selling, general and administrative expense in 2025. The Company has recorded $2.7 million in receivables related to employee stock option exercises in which the cash payment was outstanding as of June 30, 2026.

Other Receivables, net

6 Months Ended

Jun. 30, 2026

Other Receivables, Net, Current [Abstract]

6. Other Receivables, net

In April 2024, entinostat received marketing approval in China, and as a result, the Company recorded $3.5 million of milestone revenue in 2024. The Company had recorded a $3.7 million receivable related to milestones (plus accrued interest) under the license agreement with Eddingpharm in 2025, which remains outstanding as of June 30, 2026. As the receivable remains outstanding, and the Company has assessed the amount as non-recoverable, the Company recorded a full reserve against the asset as a selling, general and administrative expense in 2025.

The Company has recorded $2.7 million in receivables related to employee stock option exercises in which the cash payment was outstanding as of June 30, 2026.